CDKN2A and glioma: The system should span all glioma marker mutations—DNA sequence alterations—IDH1 R132, IDH2 R172, TP53 (W146, R175, R248, and R273), p-TERT (C250T and C228T), BRAF V600E, and H3-3A K27M; CNAs — 1p/19q-codeletion and chr +7/-10; change in particular gene expression—gain of EGFR, KIT, and PDGFRA, loss of ATRX, PTEN, and CDKN2A/B; small indels—EGFRvIII; fusions—BRAF-KIAA1549 (Figure 3) (Faulkner et al., 2015).